ABSTRACT

Introduction: Vaccination against foot-and-mouth disease virus is regarded as the most effective way to prevent disease. Selection of appropriate vaccine strains is challenging due to lack of cross-protection between serotypes and incomplete protection between some strains within a serotype. Vaccine effectiveness can be affected by vaccine formulation, vaccination approaches, and also by emerging field variants. Therefore, a precise evaluation of the protective capacity of the selected vaccine virus is essential.

Areas covered: This article discusses the limitations of currently in use in vitro methods to assess the protective capacity of vaccine strains. It includes the assessment of well-established South American vaccine strains, O₁/Campos and A₂₄/Cruzeiro, against outbreaks/emergencies in the continent, as well as against recent isolates from East and Southeast Asia.

Expert opinion: In vitro methods, and particularly r₁ values, used to evaluate the protective capacity of vaccine strains are not conclusive and do not cover the variety of field scenarios. At present, an option when facing emergencies could be to use well-established vaccine strains with broad antigenic/immunogenic coverage, including conditions that lead to increased coverage such as vaccine formulations and vaccination schemes.

摘要

简介： 接种口蹄疫病毒疫苗被认为是预防疾病的最有效方法。由于缺乏血清型之间的交叉保护和血清型内某些毒株之间的保护不完全，选择合适的疫苗毒株具有挑战性。疫苗的有效性会受到疫苗配方、疫苗接种方法以及新出现的现场变异的影响。因此，对所选疫苗病毒的保护能力进行精确评估至关重要。

涵盖的领域：本文讨论了目前用于评估疫苗株保护能力的体外方法的局限性。它包括对成熟的南美疫苗毒株 O ₁ /Campos 和 A ₂₄ /Cruzeiro进行评估，以应对非洲大陆的爆发/紧急情况，以及针对东亚和东南亚最近的分离株。

专家意见：用于评估疫苗株保护能力的体外方法，尤其是 r ₁值不是结论性的，也不能涵盖各种现场情况。目前，面临紧急情况时的一种选择可能是使用具有广泛抗原/免疫原性覆盖的成熟疫苗株，包括导致覆盖率增加的条件，例如疫苗配方和疫苗接种计划。